Efficacy, safety and immunogenicity of a recombinant human papillomavirus bivalent (types 16, 18) vaccine in healthy 18-30-year-old Chinese women: a phase III, double-blind, randomized, controlled trial.

Shi L, Gao X, Huang L, Gao Z, Li J, Yu B, Fan H, Li G, Wang Y, Li Q, Yuan L, Li C, Mo Z, HPV1003 Study group, Li Shi, Ke Li, Min Ji, Ya-Lin Hu, Ling-Yun Zhou, Xue-Mei Yan, Jing-Jing Chen, Wei Li, Zi-Long Wang, Zhen Huang, Yu-Liang Zhao, Rong-Cheng Li, Yan-Ping Li, Nian-Min Shi, Qiang Lu, Bin He, Shi-Fang Wen, Dong-Zhang Yang, Guo-Gang Liu, Yan-Xia Cai, Wei-Jiang Cui, Jiang-Bing Zheng, Zhan-Bo Geng, Yan-Hua Xie, Yong-Biao Ren, Hai-Song Zhou

Open source

DOI
10.1186/s12879-025-12064-1
Published
2025 Dec 18
Container
BMC infectious diseases
Publisher
Not recorded
Open access
yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1186/s12879-025-12064-1,
  title = {Efficacy, safety and immunogenicity of a recombinant human papillomavirus bivalent (types 16, 18) vaccine in healthy 18-30-year-old Chinese women: a phase III, double-blind, randomized, controlled trial.},
  author = {Shi L and Gao X and Huang L and Gao Z and Li J and Yu B and Fan H and Li G and Wang Y and Li Q and Yuan L and Li C and Mo Z and HPV1003 Study group and Li Shi and Ke Li and Min Ji and Ya-Lin Hu and Ling-Yun Zhou and Xue-Mei Yan and Jing-Jing Chen and Wei Li and Zi-Long Wang and Zhen Huang and Yu-Liang Zhao and Rong-Cheng Li and Yan-Ping Li and Nian-Min Shi and Qiang Lu and Bin He and Shi-Fang Wen and Dong-Zhang Yang and Guo-Gang Liu and Yan-Xia Cai and Wei-Jiang Cui and Jiang-Bing Zheng and Zhan-Bo Geng and Yan-Hua Xie and Yong-Biao Ren and Hai-Song Zhou},
  year = {2025},
  journal = {BMC infectious diseases},
  doi = {10.1186/s12879-025-12064-1},
  url = {https://doi.org/10.1186/s12879-025-12064-1}
}

RIS

TY  - JOUR
TI  - Efficacy, safety and immunogenicity of a recombinant human papillomavirus bivalent (types 16, 18) vaccine in healthy 18-30-year-old Chinese women: a phase III, double-blind, randomized, controlled trial.
AU  - Shi L
AU  - Gao X
AU  - Huang L
AU  - Gao Z
AU  - Li J
AU  - Yu B
AU  - Fan H
AU  - Li G
AU  - Wang Y
AU  - Li Q
AU  - Yuan L
AU  - Li C
AU  - Mo Z
AU  - HPV1003 Study group
AU  - Li Shi
AU  - Ke Li
AU  - Min Ji
AU  - Ya-Lin Hu
AU  - Ling-Yun Zhou
AU  - Xue-Mei Yan
AU  - Jing-Jing Chen
AU  - Wei Li
AU  - Zi-Long Wang
AU  - Zhen Huang
AU  - Yu-Liang Zhao
AU  - Rong-Cheng Li
AU  - Yan-Ping Li
AU  - Nian-Min Shi
AU  - Qiang Lu
AU  - Bin He
AU  - Shi-Fang Wen
AU  - Dong-Zhang Yang
AU  - Guo-Gang Liu
AU  - Yan-Xia Cai
AU  - Wei-Jiang Cui
AU  - Jiang-Bing Zheng
AU  - Zhan-Bo Geng
AU  - Yan-Hua Xie
AU  - Yong-Biao Ren
AU  - Hai-Song Zhou
PY  - 2025
JO  - BMC infectious diseases
DO  - 10.1186/s12879-025-12064-1
UR  - https://doi.org/10.1186/s12879-025-12064-1
ER  - 

APA

L, S., X, G., L, H., Z, G., J, L., B, Y., H, F., G, L., Y, W., Q, L., L, Y., C, L., Z, M., group, H. S., Shi, L., Li, K., Ji, M., Hu, Y., Zhou, L., Yan, X., Chen, J., Li, W., Wang, Z., Huang, Z., Zhao, Y., Li, R., Li, Y., Shi, N., Lu, Q., He, B., Wen, S., Yang, D., Liu, G., Cai, Y., Cui, W., Zheng, J., Geng, Z., Xie, Y., Ren, Y., & Zhou, H. (2025). Efficacy, safety and immunogenicity of a recombinant human papillomavirus bivalent (types 16, 18) vaccine in healthy 18-30-year-old Chinese women: a phase III, double-blind, randomized, controlled trial.. BMC infectious diseases. https://doi.org/10.1186/s12879-025-12064-1

Source records